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Abstract
The structure and function of clinical dosage insulin and its analogues were assessed. This
included ‘native insulins’ (human recombinant, bovine, porcine), ‘fast-acting analogues’
(aspart, glulisine, lispro) and ‘slow-acting analogues’ (glargine, detemir, degludec). Analyti-
cal ultracentrifugation, both sedimentation velocity and equilibrium experiments, were
employed to yield distributions of both molar mass and sedimentation coefficient of all nine
insulins. Size exclusion chromatography, coupled to multi-angle light scattering, was also
used to explore the function of these analogues. On ultracentrifugation analysis, the insulins
under investigation were found to be in numerous conformational states, however the major-
ity of insulins were present in a primarily hexameric conformation. This was true for all native
insulins and two fast-acting analogues. However, glargine was present as a dimer, detemir
was a multi-hexameric system, degludec was a dodecamer (di-hexamer) and glulisine was
present as a dimer-hexamer-dihexamer system. However, size-exclusion chromatography
showed that the two hexameric fast-acting analogues (aspart and lispro) dissociated into
monomers and dimers due to the lack of zinc in the mobile phase. This comprehensive
study is the first time all nine insulins have been characterised in this way, the first time that
insulin detemir have been studied using analytical ultracentrifugation and the first time that
insulins aspart and glulisine have been studied using sedimentation equilibrium. The struc-
ture and function of these clinically administered insulins is of critical importance and this
research adds novel data to an otherwise complex functional physiological protein.
PLOS ONE | https://doi.org/10.1371/journal.pone.0195010 March 29, 2018 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Adams GG, Meal A, Morgan PS, Alzahrani
QE, Zobel H, Lithgo R, et al. (2018)
Characterisation of insulin analogues
therapeutically available to patients. PLoS ONE 13
(3): e0195010. https://doi.org/10.1371/journal.
pone.0195010
Editor: Israel Silman, Weizmann Institute of
Science, ISRAEL
Received: January 12, 2018
Accepted: March 14, 2018
Published: March 29, 2018
Copyright: © 2018 Adams et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: Dr. Gary Adams is a non-executive
director for the Independent Diabetes Trust and
accepts no remuneration for the role. Dr’s Hanne
Zobel and Simon Ballance are employees of
Nofima AS, however this organisation did not play
a role in the study design, data collection and
analysis, decision to publish, or preparation of the
manuscript and only provided financial support in
Introduction
A fundamental intention of insulin therapy is to mimic ‘normal’ physiological insulin secre-
tion patterns, thus controlling basal and mealtime plasma glucose and fatty acid turnover
optimising blood glucose control [1]. Under physiological conditions, prandial insulin
secretion, which begins rapidly in response to autonomic activity and incretins, continuing
with the rise in glucose and amino acid concentrations, is modulated on a 3–10 min time-
frame; this is impossible to imitate without intravascular glucose sensing and insulin deliv-
ery [2].
In Diabetes Mellitus (DM), normal physiological processes do not occur and chronic
hyperglycaemia is observable, where glycaemic control is severely impaired because of prevail-
ing deficiencies in insulin or its action [3]. This insufficiency precipitates metabolic and degen-
erative microvascular and macrovascular complications in multiple organs including the
heart, nerves, eyes and kidneys. Historically, bovine and porcine insulins were used to treat
patients presenting with diabetes mellitus. Presently, insulins used at meal-times are associated
with a lag-phase post-injection before absorption begins, a delay to peak because of tissue dif-
fusion and long-acting insulins could potentially impact on physiological function initiating
aberrant cell cycle progression [4,5]. In addition, mean glucose control remains poor in clinical
practice, the challenge of hypoglycaemia continues to be problematic and user convenience
still prevails.
Insulin is a hormonal protein consisting of two chains of 21 and 30 amino acids. A sche-
matic of the amino acid primary sequence is shown in Fig 1. Insulin forms complex oligomeric
structures including, but not limited to, dimers and hexamers. Hexamers are typically stabi-
lised with two zinc ion ligands. These oligomeric states are used to control the activity of insu-
lin; it is the monomeric species which is most effective at reducing blood glucose, whereas the
hexameric form is the most stable. Insulin analogues, specifically the fast-acting insulins, have
been designed to prefer the monomeric and dimeric state, and thus increase the speed at
which they enact a hypoglycaemic response. The mechanism for slow-acting insulin analogues
is more complex but, in general, changes have been made to increase the propensity to form
larger oligomeric states.
Numerous studies have examined different synthetic insulins using a range of different
techniques [6,7]. However, in an attempt to understand further the structural characteristics of
each synthetic insulin in relation to their relative clinical performance we have characterised,
for the first time, all six clinically-available insulin analogues, as well as ‘native’ bovine, porcine
and human insulins (shown in Fig 1), using gold-standard hydrodynamic methods with the
most up-to-date analysis techniques.
Materials and methods
Insulins
Insulin analogues were sourced from commercial manufacturers as 10mL, 100U/mL (~3.5mg/
mL) vials for injection except for detemir (IDet) and degludec (IDeg) which were obtained as
3mL vials for FlexTouch1 pens as a kind gift from the InDependent Diabetes Trust (IDDT).
For categorisation, recombinant human, bovine and porcine insulins (IHr, IBov, IPor) are
referred to as ‘Native insulins’, aspart, glulisine and lispro (IAsp, IGlu, ILis) are ‘Fast analogues’
and glargine, detemir and degludec (IGla, IDet, IDeg) are ‘Slow analogues’. Samples remained
as their original preparations i,e, including all excipients present in the vial.
IHr, IAsp, IDet and IDeg were purchased from Novo Nordisk under the trade names
ActRapid1, NovoRapid1 (a.k.a. NovoLog1 in USA), Levemir1 and Tresiba1 respectively.
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IHr and IAsp arrived as 100U/mL insulin, or 3.5mg/mL. IDeg was 3.6mg/mL, IDet was
14.2mg/mL, but both were the same potency/dose (100U/mL).
IGlu and IGla were purchased from Sanofi Aventis under the trade names Apidra1 and
Lantus1, respectively. IBov and IPor were from Wockhardt, trade names Hypurin1 Bovine
neutral and Hypurin1 Porcine neutral. ILis was purchased from Eli Lilly under the trade
name Humulog1.
All insulins were stored refrigerated at 4–8˚C and allowed to equilibrate to room tempera-
ture directly before analysis. Samples were analysed before their use-by date.
Sequence properties
Sequences were inputted into SEDNTERP [8] to estimate partial specific volume (v), hydration
(δ) and isoelectric points (pI). Values are shown in supplemental data (S1 Table).
Density and viscosity measurements
Solution density was measured using an Anton Paar DMA5000 oscillating capillary density
meter (Anton Paar GmbH, Graz, Austria). Solution viscosity was measured using an Anton
Paar AMVn rolling ball viscometer (6 d.mm silanised capillary, 5 d.mm steel ball). All mea-
surements were performed at 20.00˚C, controlled to within ±0.005˚C, and are shown in S1
Table.
Dynamic light scattering
Hydrodynamic radii were measured using Dynamic Light Scattering (DLS) in a Malvern Zeta-
sizer NanoZS DLS (Malvern Instruments, Malvern, UK) at high scattering angle (173˚) to
minimise the effects of dust and supramolecular contamination (NIBS, 173˚). Dynamic viscos-
ity, required to convert diffusion coefficients to hydrodynamic radius (via the Stokes-Einstein
equation), was taken from AMVn measurements. Plastic disposable cuvettes were capped and
allowed to temperature equilibrate to (20.0±0.05)˚C. Three replicates were made of each. Data
were acquired using Zetasizer Software v6.22 (Malvern), based on the method of Provencher
[9]. Results are shown in supplemental data (S2 Table, S1 Fig).
Fig 1. Primary structure of human insulin and its analogues. Differences highlighted and numbered.
https://doi.org/10.1371/journal.pone.0195010.g001
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Size exclusion chromatography coupled to multi angle light scattering
(SEC-MALS)
Molar mass distributions were measured using SEC-MALS [10]. A Shimadzu (Kyoto, Japan)
HPLC system was used in this investigation comprising a DGU-20A 3R degasser, LC-20AD
pump, SIL-20A HT autosampler, CTO-20A column oven and CBM-20A communications mod-
ule. The system was equilibrated with three different mobile phases, including two physiological
buffers: PBS (10mmol PO4
3-, 137mmol NaCl, 2.7mmol KCl, 0.35% cyclohexanol, 0.02% NaN3,
pH measured at 7.4), and TRIS (10mmol TRIS, 140mmol NaCl, 0.35% cyclohexanol, 0.02%
NaN3, pH adjusted to 7.7 with 1mol HCl); and a neutral, unbuffered Nitrate solution (100mmol
NaNO3, 0.35% cyclohexanol, 0.02% NaN3). No zinc ions were added to any of the mobile phases.
Mobile phases were chosen to represent physiological buffering systems, in which most of the
insulins are already solvated, as well as an unbuffered, control system. 100μL of insulin samples
(unmodified from their injectable drug formulations) were auto-injected into the mobile phase
with a flowrate of 0.5mL/min. This size exclusion chromatography (SEC) column (30cm
G3000PWXL, with a 12 μm pore TSK PWXL guard column) was coupled to an 8-angle DAWN1
HELEOS1 II Multi-Angle Light Scattering (MALS) detector (Wyatt Technology, Santa Barbara,
CA, USA), using a laser wavelength of 663.4nm, and Optilab1 T-rEX1 Differential Refractive
Index Detector (Wyatt Technology) with a laser wavelength of 658nm. Data were acquired and
analysed using ASTRA software v6.1.7.15 (Wyatt Technology). Elution plots from light scatter-
ing are presented in the main paper and differential refractive index shown in S3 Fig.
Sedimentation velocity
Sedimentation coefficients and distributions were measured using sedimentation velocity ana-
lytical ultracentrifugation (SV-AUC), carried out using a Beckman Optima XL-I analytical
ultracentrifuge (Beckman, Palo Alto, USA). Analytical ultracentrifuge cells were 2-channel
(for solution and reference solvent) comprising 12mm aluminium-epoxy resin centrepieces
and sapphire windows. 400μL of insulin preparations, along with a PBS buffer reference sam-
ple, were centrifuged at 45k rev/min (~155k g) at (20.0±0.1)˚C and Rayleigh Interference scans
taken every two minutes to measure their rates of sedimentation.
Scans were analysed using the c(s) vs. s algorithm in SEDFIT [11] v14.6e which is capable of
yielding sedimentation coefficient distributions from individual scan sets and provide an esti-
mate for the molar mass using a weight-average frictional ratio (f/f0). 100 scans were loaded to
represent near-complete sedimentation, in approximately the first 10 hours of centrifugation.
Sedimentation coefficients, s, were corrected to standard conditions, namely the density and
viscosity of water at 20.0˚C to yield s20,w values.
Sedimentation equilibrium
Sedimentation equilibrium AUC (AUC-SE) was performed on the same instrumentation and
in the same cells as for AUC-SV (see above). 120μL of insulin preparations were centrifuged at
(20.0±0.1)˚C at a range of rotor speeds between 10k rev/min (~7.5k g) and 25k rev/min (~48k
g). Equilibrium solute distributions were recorded using Rayleigh interference optics. Scans
were analysed using SEDFIT-MSTAR [12], MULTISIG/MULTISIG-RADIUS [13] and
INVEQ [14].
SEDFIT-MSTAR was used to measure the apparent weight-average for the whole distribu-
tion, Mw,app, by the calculation of the M(r) function:
M rð Þ ¼
ðcr   caÞ
kcaðr2   a2Þ þ 2k
R r
a rðcr   caÞdr
ð1Þ
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where c is the concentration, r is the radial position, a is the meniscus radial position and k is a
constant related to rotor speed, temperature and buoyancy. The M function, extrapolated to
the cell base b, is an approximation for the apparent, weight-average molar mass. Relative
radius (r2-a2)/(b2-a2) was used to standardise the extrapolation, meaning a = 0 and b = 1. SED-
FIT-MSTAR also yielded estimates of the point or local weight average molecular weights
Mw(r) as a function of local concentration c(r) in the cell. Values were also checked by the
hinge-point analysis method which yields the Mw(r) value at the point in the cell where c(r) =
the cell loading concentration. SEDFIT-MSTAR also yielded estimates for the molar mass dis-
tribution c(M) vs M. For IDet, two speed analysis was used to extrapolate to a single point and
provide information on a multi-component system. Otherwise, only one, averaged, scan was
used for MSTAR analysis.
The MULTISIG algorithm was also applied to the sedimentation equilibrium distributions
and was used to assess the distribution of molar mass. It was performed with 20 repeat fits at
the hinge point and averaged to yield molar mass distributions, namely f(M) vs. M and the cor-
responding, number, weight, z-average molar masses for the distribution. For MULTISIG-RA-
DIUS, the baseline was fixed to the previously fitted value from MULTISIG and f(M) vs. M
was measured over the entire cell at 20 radial positions. The MULTISIG routine is capable of
yielding multi-component/heterogeneous distributions although assumes thermodynamic
non-ideality.
Although non-ideality effects are usually negligible when dealing with small molecules such
as insulin–and the small concentration usually needed (<0.5mg/mL), because of the high con-
centrations being used in this study, non-ideality was probed using a variation of the INVEQ
algorithm, which provides an estimate for the second thermodynamic virial coefficient B (mL.
mol.g-2), or this value multiplied by the molar mass, M, BM (mL/g). The factor (1+2BMc),
where c is the concentration (in g/mL) represents the factor by which the apparent molar
mass, Mapp measured at concentration c underestimates the true mass M. To a first approxi-
mation:
1
MappðcÞ
¼
1
M
 
1þ 2BMcð Þ ð2Þ
Results
Clinically available insulin analogues, using excipient content, solution attributes (density, vis-
cosity), sedimentation behaviour (velocity and equilibrium) and static light scattering proper-
ties, were assessed in order to obtain stoichiometric and behavioural properties.
Stoichiometry and structure
Solution properties. S1 Table shows the measured density and viscosity of the insulin
preparations, as well as estimated parameters from SEDNTERP [15].
Dynamic light scattering. S2 Table summarises the hydrodynamic radius information
obtained through dynamic light scattering (DLS). The distribution is also shown in S1 Fig.
Typical hydrodynamic radii were 2–3nm, with smaller radii obtained for IGla and IDeg. Dif-
ferences in radii cannot be reliably correlated to stoichiometry, but do provide a general trend.
Peak volume percentages were all 100%. Since DLS is more sensitive to larger species than
small, these findings strongly suggest no aggregates were present in any of the formulations.
Sedimentation velocity. Scans were analysed using a c(s) fitting algorithm. Raw data (100
scans per sample) are shown in S2 Fig. along with superimposed fits as well as residual plots,
Weight average sedimentation coefficients are shown in Table 1, obtained from distributions
shown in Fig 2. Native insulins shared a similar sedimentation coefficient at 3S, however there
Therapeutic insulin analogue characterisation
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is evidence of a small amount of sedimenting material at 5.5S for IHr (3% of distribution),
which also showed a slightly slower sedimentation coefficient than IBov and IPor. No species
were observed faster than 10S, and all macromolecular material was accounted for in the
areas-under-the-curves, therefore no aggregation was present in these samples.
Fast-acting analogues shared similar behaviour to the native insulins, apart from IGlu
which sedimented in three discrete peaks at 1.5 (8%), 2.7 (19%) and 3.8S (74%). Areas-under-
the-curves, indicating the concentration of the macromolecular components, were consistent
with 3.5mg/mL for all three analogues. This information, combined with a lack of species
beyond 10S, suggest no aggregate was present in any of the native insulins.
Slow-acting analogues showed very different behaviour to native insulins and fast-acting
analogues. IGla yielded a slower sedimenting peak at 2S. IDet sedimented at 3S (66%), but also
showed peaks at 0.8 (4%), 5.5 (21%), and 7S (8%). This indicates a multi-hexameric conforma-
tion (1x hexamer, 2x hexamer, 3x hexamer) and potentially the insulin monomer at 0.8S. IDeg
sedimented with a main peak at 3.8S (90%) and a smaller peak at 0.5S (8%).
It should be noted that these samples were analysed at single concentration, at 3,5mg/mL
(or 14.2mg/mL for IDet) and therefore may show a degree of non-ideality unaccounted-for by
the c(s) algorithm. Therefore these sedimentation coefficients are likely to be underestimates
of the true sedimentation coefficient. However, non-ideality was measured using AUC-SE.
These values, shown as the second virial coefficient BM, are shown in Table 1.
Sedimentation equilibrium. From SEDFIT-MSTAR (Fig 3), native insulins all showed
monodisperse systems at 20, 32 and 31 kg/mol for IHr, IBov and IPor, respectively. These
molar masses are consistent with the approximate value for hexamer (36 kg/mol), consistent
with findings from AUC-SV. However, the apparent mass of IHr was smaller than the IBov
and IPor, which may be an indication of non-ideal behaviour. This was confirmed with
INVEQ, where the second virial coefficient is nearly ten times higher than IBov (see Table 1).
The distributions from SEDFIT-MSTAR were confirmed with MULTISIG-RADIUS (Fig 4).
IHr yielded ~20 kg/mol and ~30 kg/mol for IBov and IPor. A small decrease in number-,
weight- and z-averages were observed closer to the cell meniscus (low concentration end)
going down to 20 kg/mol with a sigmoidal pattern, potentially indicating a self-interacting sys-
tem. Second virial coefficients (BM) for the animal insulins fitted to 3–5mL/g, a typical value
for proteins at this concentration, however IHr fitted a BM with a ten-fold higher value. This
suggests a higher degree of non-ideality is present.
SEDFIT-MSTAR yielded similar distributions at 29 and 31 kg/mol for IAsp and ILis,
respectively. However, IGlu yielded a very broad, polydisperse distribution between 10 and 90
Table 1. Hydrodynamic parameters measured using AUC-SV and AUC-SE. Sedimentation coefficients are weight-
averaged in the cases of multi-species distributions. IGlu and IDet yielded fits with BM<0. All insulins were measured
at ~3.5mg/mL, except for IDet which was measured at 14.2mg/mL.
Insulin sedimentation coefficient
(s20,w, S)
Second virial coefficient (BM, mL/g)
IHr 3.0±0.1 20.6±0.3
IBov 3.4±0.1 2.89±0.23
IPor 3.2±0.1 5.17±0.22
IAsp 3.3±0.1 7.78±0.29
IGlu 3.4±0.1 N/D
ILis 3.2±0.1 1.65±0.05
IGla 2.0±0.1 26.5±0.2
IDet 3.8±0.1 N/D
IDeg 3.5±0.1 97.0±1.0
https://doi.org/10.1371/journal.pone.0195010.t001
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kg/mol. The weight average is indicated to be 36 kg/mol from the M extrapolation to the cell
base. These results were replicated with MULTISIG-RADIUS, except for IGlu which was
resolved into three consistent peaks throughout the concentration range at ~10, ~30 and ~65
kg/mol (dimer, hexamer, di-hexamer). This is a more resolved distribution than in Fig 3E
yielded by SEDFIT-MSTAR, and is consistent with findings from AUC-SV (Fig 2B). This het-
erogeneity proved a challenge for analysis using INVEQ, yielding a BM<0, which is potentially
an indication of self-association but may be an artefact of heterogeneous material on the fitting
algorithm. However, IAsp and ILis had very low second virial coefficients.
Slow acting analogue IGla yielded a monodisperse, but smaller, distribution at 11 kg/mol.
This is indicative of a dimer conformation. The multi-speed analysis feature in SEDFIT-M-
STAR was used on two different rotor speeds for IDet to obtain a bimodal distribution. The
weight average extrapolates to 49 kg/mol, whereas two peaks are present at 30 (hexamer) and
150 kg/mol (multi-hexamer).
Fig 2. c(s) vs. sedimentation coefficient distributions measured using AUC-SV at 45k rpm. (a) Native insulins; (b) Rapid-acting analogues; (c) Slow-acting
analogues. Monomers (M), Dimers (D), Hexamers (H), and Di and Tri Hexamers (Di/TriH) were identified by molar mass calculated through the sedimentation
coefficient and the frictional ratio.
https://doi.org/10.1371/journal.pone.0195010.g002
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IGla showed a single peak across the concentration range at 6000 g/mol using MULTISI-
G-RADIUS (smaller than obtained for SEDFIT-MSTAR). IDet only resolved one peak at ~30
kg/mol, inconsistent with results from SEDFIT-MSTAR and AUC-SV. However, AUC-SE is a
low-resolution technique for distributions and it is therefore not surprising that a parsimoni-
ous model was fitted for this dataset to only show one peak. INVEQ was used to analyse the
IDeg system, which yielded a weight-average molar mass of 33.1 kg/mol.
Excipients and function
Excipients present in preparations. The list of excipients and concentrations for native
insulins, along with fast and slow acting analogues, taken from patient information sheets and
other relevant materials, are shown in S3 Table. Zinc was present in all but three preparations:
IBov, IPor and IGlu. Phenol and/or m-cresol were present in all preparations, typically at
Fig 3. c(M) vs. molar mass distributions measured using SEDFIT-MSTAR from AUC-SE data, with superimposed M(r) extrapolations to the cell base (relative
radius = 1), and c(M) fits over raw AUC-SE data in insets. (a) IHr; (b) IBov; (c) IPor; (d) IAsp; (e) IGlu; (f) ILis; (g) IGla; (h) IDet; (i) IDeg. SEDFIT-MSTAR was unable
to adequately fit data from IDeg.
https://doi.org/10.1371/journal.pone.0195010.g003
Therapeutic insulin analogue characterisation
PLOS ONE | https://doi.org/10.1371/journal.pone.0195010 March 29, 2018 8 / 17
~3mg/mL where known. IGlu was the only insulin preparation not to contain glycerol, which
was typically present at 16mg/mL. Buffer salts were not present in IHr, IGla or IDeg, and insu-
lins which did have buffering salts were inconsistent with their concentrations and types,
although mostly contained TRIS or sodium phosphate. Polysorbate 20, also known as
Tween1 20, was present in Sanofi insulins IGlu and IGla.
Size-exclusion chromatography. Native insulins eluted at 16 minutes/8mL (MALS con-
firmed this peak to be ~30–40 kg/mol, or hexameric conformation) with small amounts of
material eluting at 10mL (100–200 g/mol, likely to be an excipient peak, e.g. glycerol).
Although the light scattering signal was high, very little signal was observed from differential
refractive index (S3 Fig) suggesting there may be very large aggregates present, which would
usually scatter large amounts of light, but in very small quantities as to not impact the refrac-
tive index. There was no apparent difference between PBS, TRIS and Nitrate for native
Fig 4. Molar mass distributions measured against concentration using MULTISIG-RADIUS from AUC-SE data, with superimposed n-, w- and z-average molar
masses. Insets are fits from INVEQ analysis. (a) IHr; (b) IBov; (c) IPor; (d) IAsp; (e) IGlu; (f) ILis; (g) IGla; (h) IDet; (i) IDeg. MULTISIG-RADIUS was unable to
adequately fit data from IDeg, but INVEQ was able.
https://doi.org/10.1371/journal.pone.0195010.g004
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insulins. The elution profiles are shown in Fig 5 and weight-average molar masses summarised
in Table 2.
Fast-acting analogues did not elute as consistently as the native insulins. Only a small
amount of IAsp material eluted at 8mL, with the majority eluting at the excipient peak (10
minutes). IGlu eluted with a broad distribution between 8 and 10mL (this was broader for PBS
than for TRIS or Nitrate). ILis eluted much later (12mL) than the excipient peak with a broad
distribution eluting as late as 13mL. There was also a difference between elutions obtained in
TRIS compared to PBS and Nitrate for ILis.
IDeg eluted at 7.5mL (MALS indicated this peak to be 60–70 kg/mol) in PBS and TRIS, and
7mL for Nitrate (270 kg/mol) with no indication of an excipient peak at 10mL as seen in other
samples. IDet eluted with multiple peaks between 6–10mL, with a shoulder peak observed at
10mL indicating the excipients. A small difference was observed between TRIS and PBS for
Fig 5. Elution from SEC plots of insulin and analogues. Black line represents PBS as the mobile phase, grey line represents TRIS. (a) IHr; (b) IBov; (c) IPor; (d) IAsp;
(e) IGlu; (f) ILis; (g) IDet; (h) IDeg. IGla was not injected due to pI/pH incompatibilities. Monomers (M), Dimers (D), Hexamers (H), Dihexamers (DiH),
multihexamers (multiH) and Excipients (Ex) were identified by molar mass.
https://doi.org/10.1371/journal.pone.0195010.g005
Therapeutic insulin analogue characterisation
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IDet: in TRIS, the main peak eluted 0.5mL earlier and there is a smaller peak at 5.5mL, how-
ever Nitrate eluted at 8mL with a MALS confirmed molecular weight of 300 kg/mol.
Discussion
Analytical ultracentrifugation
Our results indicate that native animal insulins exist primarily in the hexameric form with a
sedimentation coefficient of 3.0S and with 95% of the loading concentration. In 1931 Sjo¨gren
and Svedberg [16] investigated preparations of bovine insulin at pH ~7 by sedimentation
velocity and equilibrium, and using a partial specific volume (measured by pycnometry) of
0.750mL/g. These researchers found sedimentation coefficients ranging from 3.21–3.41 x10-13
s20, and molar mass of 35.1 kg/mol. We now know that this is consistent with the hexameric
conformation. Numerous other studies involving AUC were performed on animal insulins
(bovine and porcine) since this seminal paper all homing in on the modern interpretation of
the monomer-dimer-hexamer stoichiometry, with 5.8 kg/mol subunits [17–23], with the hex-
amer precisely stabilised and controlled with zinc ions [24–26] to a point where an excess
causes aggregation [27]. Once protein expression from micro-organisms became possible,
researchers turned their attention to human recombinant insulin, either corroborating the
findings from animal insulin experiments [28–30] or researching insulin’s fibrillation proper-
ties [31]. This investigation builds on the work of these publications by using the most recent
advances in AUC-SV and SE analysis.
Fast-acting analogues were also studied using AUC-SV and AUC-SE. IAsp and ILis were
found to exist in a mostly hexameric state, whereas IGlu was in a complex dimer-hexamer-
dihexameric state. IAsp and IGlu have only been studied using sedimentation velocity once
before by Teska et al. [32], and there have never been any publications on the use of sedimenta-
tion equilibrium on either of these analogues. Teska et al. studied the effects of phenolic preser-
vatives and zinc concentration on fast acting analogues, as well as the drug-formulation
available to patients. They found similar c(s) profiles to this present investigation, including
the three-peaked distribution from IGlu. ILis, the oldest marketed analogue available to
patients, however, has been studied more extensively [29,33]. Richards et al. [33] also used sed-
imentation equilibrium, yielding differential, point-average, molar mass against concentration
plots. No non-ideality was observed due to lower concentrations used in their study. Also,
Table 2. Weight-average molar mass estimates from AUC-SV, AUC-SE and SEC-MALS results. Estimates uncorrected for non-ideality are labelled ‘apparent’ (app).
All AUC-SV estimates were made on data from 45k rpm and based upon estimates of the frictional ratio fitted from boundary spread, and are weight averaged in the case
of multiple sedimenting species. AUC-SE analysis was made at the indicated rotor speeds in parentheses (k rpm). SEC-MALS estimates are shown as consensus values
from PBS and TRIS mobile phases. IDeg was unanalysable using MSTAR and MULTISIG. IGla was not assayed using SEC-MALS due to pI/pH incompatibilities.
Insulin AUC-SV
Mw,app
kg/mol
AUC-SE MSTAR
Mw,app
kg/mol
(k rpm)
AUC-SE MULTISIG Mw,app
kg/mol
(k rpm)
AUC-SE INVEQ
Mw
kg/mol
(k rpm)
SEC-MALS
Mw,app
kg/mol
IHr 40.3 20.1 (18) 16.9 (18) 26.8 (18) 30.0
IBov 36.0 32.2 (18) 30.1 (18) 33.3 (18) 31.9
IPor 38.1 31.6 (18) 28.8 (18) 33.5 (18) 31.5
IAsp 38.0 29.4 (18) 26.2 (18) 32.6 (18) 12.4
IGlu 29.8 35.9 (15) 32.9 (15) 44.7 (15) 24.0
ILis 36.9 31.9 (18) 31.3 (18) 33.3 (18) 10.4
IGla 21.7 8.1 (25) 8.1 (25) 14.8 (25) N/D
IDet 60.4 49.2 (10,18) 33.5 (18) 33.8 (18) 60.2
IDeg 92.2 N/D N/D 33.1 (25) 66.0
https://doi.org/10.1371/journal.pone.0195010.t002
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minimal polydispersity was observed as the molar mass remained consistent throughout the
cell in the monomeric state (5.8 kg/mol). These findings were corroborated by Hinds et al.
[30] who found the system to be entirely monomeric, using similar analysis techniques to
Richards et al [33]. The latest findings from this investigation suggested that the system was
mostly hexameric, however the results are from injectable drug formulations and would there-
fore be designed to keep the insulin in the most protective stoichiometry. It is also the first
published account of insulins aspart and glulisine analysis using AUC-SE.
It is interesting to note that the study of insulins glargine and detemir using AUC (either
SV or SE) have been limited or non-existent. IGla was reported by our group [3] as part of a
dosage study involving the single and triple dose forms and similar results are observed in this
present investigation. IDet showed interesting multi-hexameric behaviour in AUC-SV, but
this was not present in AUC-SE; possibly due to the very high concentration involved (and
therefore high signal from the main peak) as well as the low-resolving power from SE analysis.
Steensgaard et al. [34] using AUC-SV, SE as well as other complementary techniques, inves-
tigated and discovered multi-hexameric behaviour in IDeg. Steensgaard et al. posited that mul-
tihexamers combine to form long rods, or fibres, which aid in the action of retarding the
release of efficacious monomers into the bloodstream. Although we did not find similar multi-
hexameric behaviour in IDeg, we did observe dihexamers. In addition, we found a high degree
of non-ideality, confirmed from a previous investigation [3] to be a result of a lack of buffering
salts in the drug preparation. It is possible that the excipient composition in the product pre-
vents the formation of these fibres.
Size exclusion chromatography
This investigation employed SEC-MALS to assess both the quaternary structure, in the form of
stoichiometry, as well as function, in relation to the absence of zinc ions. Eight of the nine
insulins were injected into the column (IGla was incompatible with the mobile phases) and
assessed in terms of elution time and measured molar mass. IHr, IBov and IPor all behaved in
a similar fashion, eluting at the same time and existing in the hexameric state, despite having a
mobile phase void of zinc ions. This leads to two opposing possibilities to be posited; first, that
the lack of zinc ions allowed for diffusion of bound zinc from the complex, and that the intra-
protein attraction was still strong enough to maintain the hexamer; second, the binding
strength of the complex to the zinc ions was too strong to allow zinc to diffuse into the mobile
phase. From this investigation it is unclear which of these two scenarios is true, however it is
our belief that the second option is more likely.
A series of seminal papers by Brange et al. [35–39] employed size exclusion chromatogra-
phy (SEC) to study the formation of covalently bound insulin dimers in native insulins and the
effects of excipients and storage conditions. Among other findings, they suggested that the use
of phenol and phenol-like compounds reduced the incidence of covalent dimer formation.
This is the reason why these compounds were present in all formulations tested in this investi-
gation, although Brange’s research showed that effectiveness was greatest with phenol, then m-
cresol, then methyl paraben yet the insulin preparations contained mostly m-cresol. This is
likely due to the higher toxicity of phenol compared to m-cresol. Findings from this investiga-
tion showed no evidence of covalent dimers, likely due to the presence of these phenolic
preservatives.
Fast acting analogues behaved very differently from native insulins. IAsp and ILis eluted as
primarily dimers and monomers, and IGlu eluted as a monomer-dimer-hexamer stoichiome-
try. In this respect, IGlu behaved in the most similar fashion to AUC experiments. The mobile
phase also appears to have made a difference; nitrate buffer caused IGlu to form mostly
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hexamers, and ILis elutions were erratic between the three buffers. It is likely that the different
cations, being of different size and charge density, acted upon the insulins in distinct ways,
however the mode of action is not clear from this investigation.
Bakaysa et al. [29] employed static light scattering to confirm the molar mass obtained from
AUC-SE for ILis, although this was not combined with a chromatographic column. They
found the system to act in a similar, dimeric fashion, however in this investigation the two
techniques yielded different molar masses. ILis showed a broad monomer-dimer distribution
eluting the column much later, and confirmed with MALS. This is due to the presence of
excipients and zinc ions in AUC-SE which would have diffused away from the bolus and
caused the system to dissociate. The same phenomenon should have occurred for the native
insulins if it were not for the fact that these fast acting analogues were designed to dissociate in
this way, and is in agreement with the mode of action in vivo, where fast-acting analogues are
injected subcutaneously and dissociate into the more effective monomer form faster than reg-
ular insulin. Similar conclusions were drawn by Gast et al., [40] who also studied the associa-
tion/dissociation kinetics of these fast acting analogues.
IGla has been previously studied using DLS [41,42]. Both studies found IGla to exist in
large aggregates in pH 7 due to the isoelectric point matching the buffer. In this investigation
(S2 Table), the drug formulation showed IGla to exist as very small oligomers–although DLS is
not sensitive enough to precisely indicate in which oligomeric state it exists, the results are
consistent with the findings from AUC-SV that showed the presence of dimers (in that the
particle size was significantly smaller than the hexameric insulins). Nakazawa et al. [41] also
studied IDet using DLS, but is the only paper to publish on this method for this analogue.
They found the hydrodynamic diameter of IDet to be larger than IHr, ILis and IGlu, consistent
with findings from this investigation.
Havelund et al. [43] studied IDet, in the context of the phenomenon of albumin binding,
using SEC. They used TRIS-buffered saline at 37˚C in the presence and absence of 2mmol/L
phenol, as opposed to this investigation studying all analogues in the presence of cyclohexanol,
an equivalent compound, in three different buffering systems. Havelund et al. also found IDet
to form a hexamer-dihexamer equilibrium but no higher-order multihexamers. However,
these findings may be due to the concentration range used, as they injected 3.5mg/mL whereas
14mg/mL was used for this investigation, the concentration which is clinically applicable to
this insulin.
Conclusions
Nine clinically available and administered insulins and analogues have been examined using
hydrodynamic and light scattering techniques. This is the first time all nine insulins have been
assessed in this way, the first time that analytical ultracentrifugation has been employed on
insulin detemir, and the first time that insulins aspart and glulisine have been assayed using a
sedimentation equilibrium experiment in publication. Analytical ultracentrifugation revealed
the quaternary structures of all nine insulins, revealing complex, but clinically important, stoi-
chiometries. Size exclusion chromatography then showed the function of these analogues
when zinc, the ligand critical to the structure and stability of the insulin hexamer, was removed
from the mobile phase. These characteristics are important for future developments in insulin,
and in developing new personalised treatments for diabetes.
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S1 Fig. Distributions (volume percentage against hydrated radius) obtained through
dynamic light scattering. (a) native insulins, (b) fast-acting analogues, (c) slow-acting
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(EPS)
S2 Fig. Raw data and superimposed fits from 100 scans taken over the course of sedimenta-
tion velocity experiments of all nine insulins. Residual plots (fit-raw) are shown under-
neath sedimentation profiles. (a) IHr, (b) IBov, (c) IPor, (d) IAsp, (e) IGlu, (f) ILis, (g) IGla,
(h) IDet, (i) IDeg.
(TIF)
S3 Fig. Elution profiles of insulins by three different mobile phases (PBS, TRIS and
Nitrate) detected by differential refractive index. (a) IHr, (b) IBov, (c) IPor, (d) IAsp, (e)
IGlu, (f) ILis, (g) IDet, (h) IDeg.
(EPS)
S1 Table. SEDNTERP output and density/viscosity properties for insulin and analogue
samples at 20˚C.
(DOCX)
S2 Table. Results from dynamic light scattering of insulin and analogues. Measurements
taken at an angle of 173˚ and at 20˚C.
(DOCX)
S3 Table. List of excipients found from patient safety information sheets, and related liter-
ature, for insulin and analogues (per millilitre of preparation). +, the excipient is mentioned
but not quantified. -, not present or not mentioned. Trace, as presented in documentation.
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